A phase I trial and a preclinical study found viral immunotherapy triggered T cell responses in glioblastoma. The clinical study enrolled 41 patients; the mouse study showed prolonged survival and immunologic memory.
Regeneron and Parabilis Medicines entered a research collaboration focused on Antibody-Helicon Conjugates. The deal includes $125 million upfront and financing support and up to $2.2 billion in milestones.
Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
Crescent Biopharma dosed the first patient in its ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company also reported Q1 2026 results and outlined pipeline milestones including ADC combination trials expected in the second half of 2026.
Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.
Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602855 |
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07591155 |
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07590648 |
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07583953 |
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07558200 |
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07545356 |
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07538479 |
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07537881 |
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07529002 |
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors |
RECRUITING | |
| NCT07522073 |
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma |
RECRUITING | PHASE3 |
